All Stories

  1. Sodium-Glucose Cotransporter-2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Discontinuation in Patients with CKD
  2. Does Serum Creatinine Reflect Muscle Mass in Patients with Kidney Failure?
  3. Effects of the 2021 CKD-EPI Creatinine eGFR Equation among a National US Veteran Cohort
  4. Considerations in the Study of Body Mass Index Variability
  5. Are All SGLT2 Inhibitors Created Equal?
  6. Effects of Treatment of Metabolic Acidosis in CKD
  7. Facility-Level Variations in Kidney Disease Care among Veterans with Diabetes and CKD
  8. Facility-level variation in diabetes and blood pressure control in patients with diabetes: Findings from the Veterans Affairs national database
  9. Pragmatic Randomized, Controlled Trial of Patient Navigators and Enhanced Personal Health Records in CKD
  10. Omega‐3 Fatty Acids (Fish Oil) Supplementation and Albuminuria: Not a Slam Dunk
  11. BP Targets in Older Adults with CKD: Additional Evidence, but Uncertainty Continues
  12. Chronic Renal Insufficiency Cohort Study (CRIC): Overview and Summary of Selected Findings
  13. Implantable Cardioverter-Defibrillators in Patients with CKD: A Propensity-Matched Mortality Analysis
  14. Urinary Creatinine Excretion, Bioelectrical Impedance Analysis, and Clinical Outcomes in Patients with CKD: The CRIC Study
  15. Presence and Outcomes of Kidney Disease in Patients with Pulmonary Hypertension
  16. Aldosterone Breakthrough during Angiotensin Receptor Blocker Use: More Questions than Answers?
  17. Cardiac Resynchronization Therapy in CKD: A Systematic Review
  18. Metabolic Syndrome, ESRD, and Death in CKD
  19. Impact of Navigators on Completion of Steps in the Kidney Transplant Process: A Randomized, Controlled Trial
  20. Fibroblast Growth Factor 23 and Inflammation in CKD
  21. Aldosterone antagonists for preventing the progression of chronic kidney disease